Pages that link to "Q80647000"
Jump to navigation
Jump to search
The following pages link to The fate of antipyrine in man (Q80647000):
Displaying 50 items.
- 4,4?-Dihydroxyphenazone as an urinary metabolite of phenazone in different species including man (Q28328809) (← links)
- The relationship between liver volume, antipyrine clearance and indocyanine green clearance before and after phenobarbitone administration in man. (Q30498597) (← links)
- Effect of flurbiprofen on the metabolism of antipyrine in man (Q33568400) (← links)
- Genetic control of dicumarol levels in man (Q34281294) (← links)
- Genetic control of the phenobarbital-induced shortening of plasma antipyrine half-lives in man. (Q34283194) (← links)
- Disposition of antipyrine in African patients with Hodgkin's lymphoma (Q34417385) (← links)
- The plasma half-life of antipyrine in chromic uraemic and normal subjects (Q34451714) (← links)
- Altered elimination of antipyrine in patients with acute viral hepatitis (Q34471989) (← links)
- Drug metabolism in hepatosplenic schistosomiasis in the Sudan: a study with antipyrine (Q34474922) (← links)
- Antipyrine clearance per unit volume liver: an assessment of hepatic function in chronic liver disease (Q34475680) (← links)
- Assessment of the drug metabolism capacity of the liver (Q34511238) (← links)
- Factors influencing antipyrine elimination (Q34515853) (← links)
- Drug metabolism in epileptics: in vivo and in vitro correlations (Q34516209) (← links)
- Liver size and indices of drug metabolism in epileptics (Q34516957) (← links)
- Impairment of drug metabolism in polycystic non-parasitic liver disease (Q34518264) (← links)
- Verapamil favorably influences hepatic microvascular exchange and function in rats with cirrhosis of the liver (Q34533948) (← links)
- Drug metabolism in malnourished children: a study with antipyrine (Q34987130) (← links)
- Interactions between nutritional factors and drug biotransformations in man (Q35012384) (← links)
- Genetic and environmental factors affecting host response to drugs and other chemical compounds in our environment (Q35132895) (← links)
- Genetic variation in rates of antipyrine metabolite formation: a study in uninduced twins (Q35469675) (← links)
- Comparative concentrations of cefoxitin in human lungs and sera (Q35770258) (← links)
- Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance: Extrapolation of data to benzodiazepines and phenytoin (Q36587604) (← links)
- Monogenic control of variations in antipyrine metabolite formation. New polymorphism of hepatic drug oxidation (Q36989899) (← links)
- Validation of the use of nonnaive surgically catheterized rats for pharmacokinetics studies. (Q37204013) (← links)
- Research review. Interactions between environmental chemicals and drug biotransformation in man. (Q37855993) (← links)
- Measurement of urinary 6-?-hydroxycortisol excretion as an in vivo parameter in the clinical assessment of the microsomal enzyme-inducing capacity of antipyrine, phenobarbitone and rifampicin (Q39247518) (← links)
- Effect of human renal and hepatic disease on the pharmacokinetics of anticancer drugs (Q40104510) (← links)
- Assessment of Methods to Identify Sources of Interindividual Pharmacokinetic Variations (Q40108050) (← links)
- Salivary Antipyrine Kinetics in Hepatic and Renal Disease and in Patients on Anticonvulsant Therapy (Q40511110) (← links)
- Propranolol disposition in chronic liver disease: a physiological approach (Q40640567) (← links)
- Pharmacokinetic study of antipyrine in malnourished children (Q41345877) (← links)
- The effects of industrial lead poisoning on cytochrome P450 mediated phenazone (antipyrine) hydroxylation (Q41348324) (← links)
- Determinants of serum antipyrine half-lives in patients with liver disease (Q41516235) (← links)
- Tolbutamide as a model drug for the study of enzyme induction and enzyme inhibition in the rat. (Q41747906) (← links)
- Effect of vitamin C supplement on antipyrine disposition in man. (Q41857500) (← links)
- Antipyrine metabolite formation in children in the acute phase of malnutrition and after recovery (Q42017833) (← links)
- Differential effects of enzyme induction on antipyrine metabolite formation (Q42021525) (← links)
- Studies on the different metabolic pathways of antipyrine in man. I. Oral administration of 250, 500 and 1000 mg to healthy volunteers (Q42285318) (← links)
- Effect of posture on ampicillin pharmacokinetics, glomerular filtration rate and renal plasma flow in resting subjects (Q42667900) (← links)
- Antipyrine kinetics in cannabis smokers (Q42877644) (← links)
- Impairment of hepatic drug metabolism in alcoholics (Q43203844) (← links)
- Antipyrine metabolite kinetics in healthy human volunteers during multiple dosing of phenytoin and carbamazepine (Q43240294) (← links)
- Histological changes in the liver and indices of drug metabolism in alcoholics (Q44785965) (← links)
- Hepatic clearance of drugs. II. Experimental evidence for acceptance of the “well-stirred” model over the “parallel tube” model using lidocaine in the perfused rat liverin situ preparation (Q44873429) (← links)
- Liver size and indices of drug metabolism in alcoholics (Q44978229) (← links)
- Antipyrine disposition and liver size in the elderly (Q47314352) (← links)
- Studies on regional blood flow of the mouse using whole-body autoradiography of 14C-iodoantipyrine (Q49039650) (← links)
- Normal antipyrine metabolism in patients with cholesterol cholelithiasis. Evidence that the disease is not due to generalized hepatic microsomal dysfunction (Q50157509) (← links)
- Regional Cerebral Blood Flow in Physiologic and Pathophysiologic States (Q51111944) (← links)
- Metabolic Ability and Enflurane Defluorination in Surgical Patients (Q51867233) (← links)